Curaleaf Just Reported Record Profit - While Losing Money | CURLF
🎙 Listen — Q&A podcast
RoboSystems Initiating Coverage · Curaleaf Holdings, Inc. · OTCQX: CURLF / TSX: CURA · FY2025 40-F (filed February 27, 2026) + Q1 2026 results · Published July 16, 2026
The Hook
In May, Curaleaf - the largest US cannabis multi-state operator by revenue - reported first-quarter net income of $70 million, its best quarterly profit ever and a swing of $120 million from the year-ago loss. Here is what the headline doesn't say: Curaleaf lost money in the first quarter. Pretax loss from continuing operations was $28.6 million. The entire profit came from a $98.7 million income-tax benefit - an accounting release of tax reserves the company had built up over two years of charging itself federal taxes it never actually paid.
That reserve is the real story. Over fiscal 2022 through 2025, Curaleaf recorded roughly $516 million of income tax expense against a cumulative pretax loss of about $402 million - a four-year effective tax rate that is deeply negative, peaking at roughly negative 158 percent in FY2025, when it booked $124 million of tax expense on a $78 million pretax loss. That is Section 280E of the tax code, which bars cannabis companies from deducting normal operating expenses because marijuana is a Schedule I substance. Curaleaf's answer, starting in 2024, was to keep charging the tax on its income statement but largely stop paying it: cash taxes paid fell from $156 million in 2022 to about $17 million in 2024 and roughly $27 million in 2025, while the "uncertain tax position" reserve on its balance sheet ballooned from $57 million at the end of 2023 to $588 million at the end of 2025. The biggest name in cannabis is running a half-billion-dollar bet against the IRS - and in Q1 it started booking the winnings before the game is over.
Company Snapshot
Curaleaf Holdings operates 164 dispensaries across the US (72 in Florida alone) plus one of the largest cultivation and manufacturing footprints in the industry, under brands including Select (the #1 vape brand by share, per Hoodie Analytics), Grassroots, Find, JAMS, and the new ultra-premium Dark Heart line. It is also the only US MSO with a real international business: Curaleaf International - now 100 percent owned after buying out the remaining 45 percent of Germany's Four 20 Pharma in April - sells medical cannabis across Europe (Germany, UK, Poland) and did $172 million of revenue in FY2025, up 63 percent. The company is a Canadian-listed 40-F filer (TSX: CURA, OTCQX: CURLF) that just took three concrete steps toward a US exchange: a 1-for-3 reverse split (June 5), shareholder approval to redomicile from British Columbia to Delaware (June 22 annual meeting), and an auditor upgrade to BDO. Its FY2025 40-F is the first Curaleaf filing with fully queryable XBRL in the RoboSystems SEC graph - which is why the biggest name in the sector is only now getting this coverage. All figures below are from that filing and the Q1 2026 earnings release unless attributed otherwise.
The Financial Story
Start with the top line, because it explains why this is a margin-and-policy story rather than a growth story. Revenue was $1.35 billion in FY2023, $1.33 billion in FY2024, and $1.27 billion in FY2025 - a plateau with a slow leak, driven by the same price compression squeezing every operator in Illinois, Nevada, and other maturing markets. Q1 2026 broke the pattern modestly: revenue of $324 million grew 6 percent year over year, ahead of guidance, with domestic up 2 percent and international up 35 percent. Management guided Q2 to roughly $333 million. The engine underneath is respectable: gross margin was 49.8 percent in FY2025 and 49 percent in Q1, and company-reported adjusted EBITDA was $275 million in FY2025 - a 22 percent margin that has held remarkably steady (22.6 percent in 2023, 22.4 percent in 2024) even as revenue slipped.
So why has this company lost money every single year? Three drains, in order. First, 280E: $124 million of tax expense in FY2025 alone, on negative pretax income. Second, debt service: Curaleaf paid $104 million of cash interest in FY2025 - about 8 percent of revenue - on roughly $565 million of notes and sizable lease obligations. It refinanced its $475 million maturity in February with a $500 million senior secured note at 11.5 percent due 2029, the largest debt raise in US cannabis history, which bought time but locked in a punishing coupon. Third, the boom-era hangover: depreciation and amortization ran $197 million, much of it amortizing $1.65 billion of goodwill and intangibles that still sit on the balance sheet - 58 percent of total assets - from the 2020-21 acquisition spree. Write-downs have been comparatively modest (roughly $51 million of goodwill impairment in 2023, $54 million of asset impairments in 2024), which either means the assets are good or the reckoning is unfinished.
The cash flow statement tells the most honest version of the story - and it cuts both ways. Operating cash flow was $138 million in FY2025 and free cash flow was positive at roughly $74 million after $63 million of capex. That looks like health. But recall that Curaleaf charged itself $164 million of current tax expense in FY2025 and paid only about $27 million in cash. Had it actually paid what 280E says it owes, operating cash flow would have been deeply negative. In other words, the company's positive cash flow is, in large part, an interest-free loan from the IRS that the IRS has not agreed to make. The unpaid balance - that $588 million uncertain-tax-position reserve, plus tens of millions in accrued interest and penalties - sits against just $106 million of cash. This is the aggressive version of what the whole sector is doing: public MSOs collectively carry roughly $1.6 billion in disputed 280E liabilities, per MJBizDaily, and the IRS is actively fighting the theory, having sued TerrAscend in May to claw back an $8.3 million refund. Curaleaf itself has claimed roughly $128 million in refunds for prior years and received about $26 million of them - money that is now precedent-exposed.
Then came Q1 2026, and the quarter that looked like the inflection. Net income of $70 million, earnings per share of $0.09 (pre-split). But the P&L anatomy matters: a $28.6 million pretax loss, converted into profit by that $98.7 million tax benefit. On the call, CFO Ed Kremer explained that a tax review completed with external counsel - notably before the April rescheduling order - concluded certain prior-year positions met the "more likely than not" standard under ASC 740, allowing the company to release a significant portion of its reserves, with more 280E benefit expected in future periods now that Treasury has confirmed medical-cannabis relief. That may prove entirely correct. But viewers should be clear-eyed: the reported profit is the accounting expression of Curaleaf's own confidence in its tax bet, released in the same quarter the company changed auditors from PKF O'Connor Davies to BDO. The operations improved modestly; the earnings swing was a judgment call.
Catalyst Scenarios - How the Math Changes
The regulatory backdrop moved more in the last three months than in the prior decade, and Curaleaf is unusually leveraged to it. On April 28, a partial federal order took effect moving FDA-approved and state-licensed medical cannabis to Schedule III - adult-use remains Schedule I. Because 280E keys off the drug's schedule, that removed 280E from medical income prospectively (effectively back to January 1, 2026 for calendar-year filers, per the announced Treasury transition rule). CEO Boris Jordan told analysts that 60 percent of Curaleaf's US business is medical - and 80 percent of the global business including Europe - so Curaleaf captures more of this partial relief than adult-use-heavy peers like Verano or Cresco. The broader prize moved too: the DEA's expedited hearing on rescheduling all marijuana ran June 29 through July 15 - it concluded yesterday - and Chief Administrative Law Judge Derek Julius now writes a recommended decision, with exceptions due within 20 days and a final call by the DEA Administrator after that. Jordan expects adult-use rescheduling "later this summer"; that is management's timeline, not ours.
Here is the switch-flip math, using Curaleaf's own FY2025 numbers as the base. Take adjusted EBITDA of $275 million, subtract $104 million of cash interest and roughly $80 million of guided capex. In the full-280E world where Curaleaf actually pays its charged current taxes of about $164 million, owner earnings are roughly negative $73 million - which is why the stock traded near its split-adjusted low of $2.83 within the past year. In the current partial-relief world (280E off roughly 60 percent of the US tax bill, state taxes and adult-use federal tax still owed), the cash tax load drops to perhaps $90-100 million and owner earnings hover near breakeven. Under broad rescheduling - 280E gone entirely, normal 21 percent federal rate applied to what is today modest pretax income, plus state taxes - cash taxes might run $25-40 million, putting owner earnings around $55-90 million, before any growth from international or the hemp migration. On the income statement the same flip shows up as roughly $124 million of annual tax expense converting to approximately zero on a pretax loss: FY2025's $202 million continuing-operations loss would have been closer to $78 million - and Q1-style reserve releases become recurring benefits rather than one-offs.
Three more catalysts stack on top. First, uplisting: Curaleaf has done the mechanical prep - reverse split, Delaware domestication approved, BDO engaged, shares resumed trading under CURLF on July 6 after the temporary CURLD post-split symbol expired - but unlike Trulieve (NYSE: TRLV since June 10), it has not announced a medical-only restructuring, and no exchange or ticker is confirmed. Jordan is explicitly waiting for broad rescheduling and Treasury guidance rather than deconsolidating adult-use. Second, the demand side: the federal intoxicating-hemp ban takes effect in November, and Jordan expects it to drive "10 to 15 percent organic growth" for the regulated sector in early 2027 - Curaleaf is exiting its own hemp lines and positioning to absorb that demand in channel states. Third, the one nobody else can copy: import-export. Curaleaf filed DEA registration applications for its medical locations in May; Jordan says the rescheduling framework could ultimately let its US farms - which supply about 80 percent of its domestic product but only 20 percent of what it sells internationally - feed its European operation, replacing planned overseas capex with high-margin exports. He cited an implied value of roughly $1 billion for Curaleaf International based on a comparable transaction. All of that is optionality, not guidance; none of it is in the current run-rate.
Valuation - What It's Worth If It's a Normal Business
Here is the uncomfortable part for the bulls: Curaleaf already trades like the catalysts happened. At $9.70 (July 15 close), the market cap is about $2.6 billion; add roughly $930 million of debt and leases and subtract $106 million of cash, and the enterprise value is near $3.4 billion - about 12-13 times FY2025 adjusted EBITDA of $275 million. The Tier 1 MSO comp set trades at 3 to 5.5 times (Verano 3.3x, Trulieve 4.8x, Green Thumb 5.3x, Cresco 5.4x, per SSC Advisors comps priced May 29), while consumer-staples and CPG names - the "normal business" benchmark - trade around 10 to 14 times. Run the cross-sector re-rating on Curaleaf and you get a striking answer: at CPG multiples of 10 to 14 times EBITDA, implied equity value is roughly $1.9 to $3.0 billion, or about $7 to $11 per share. Today's price sits at the top of that band. The re-rating trade that still exists in Green Thumb or Verano has, for Curaleaf, largely already happened - the market has awarded it a normal-company multiple in advance, presumably for the international business, the uplisting path, and the medical-heavy mix.
A scenario DCF says the same thing with different words. Assume a 12 to 14 percent discount rate (still an OTC-traded, litigation-exposed name), 2 percent terminal growth, and the owner-earnings paths above. In a base case where broad rescheduling stalls and the partial order survives but nothing more - owner earnings near breakeven, international growing 25-30 percent on a small base - the operating business supports something like $3 to $5 per share, with most of the value in Europe and the asset base. In the full-catalyst case - broad Schedule III in 2026-27, prospective relief holds, back taxes settled without punitive outcomes, modest hemp-migration lift - owner earnings of $60-90 million growing mid-single digits support roughly $7 to $11. And in the whipsaw case, where the D.C. Circuit stays or vacates the partial order, the Q1 reserve release logic reverses, the $588 million liability hardens with interest compounding daily, and the equity math gets ugly fast against $106 million of cash. These are implied values under stated assumptions, not price targets. What today's $9.70 tells you is that the market is pricing the full-catalyst path at close to full probability - you are not being paid to wait for the catalyst; you are being asked to pay for it up front.
Risks and Open Questions
The concentrated risk is legal, and it has three heads. One: the pending D.C. Circuit challenge to the April order - a stay motion was still undecided as of mid-July - which, if granted, removes the Schedule III predicate under both the medical 280E relief and the Q1 accounting release, forcing potential reversals (auditors are already telling MSOs to keep robust ASC 740 reserves, per Crowe). Two: the back-book. Prospective relief does not erase the $588 million uncertain-tax-position reserve; there is no amnesty program, offers-in-compromise are effectively closed to cannabis companies (the Tax Court's Mission Organic decision upheld the IRS's math), interest compounds daily, and the TerrAscend clawback suit shows the IRS will litigate refunds already paid - including, potentially, the roughly $26 million Curaleaf has received. Three: the Ohio attorney general's antitrust suit naming Curaleaf among nine MSOs alleged to have coordinated pricing - unresolved and largely unpriced. Beyond the legal stack: $565 million of 11.5 percent debt and $104 million of annual interest make Curaleaf the most levered Tier 1 name; price compression continues in several core states; the temporary-equity accretion ($97 million in FY2025) and non-controlling interests quietly dilute common holders; and this remains a 40-F filer with messier disclosure than a 10-K company - our own graph shows occasional tagging errors in the filing's XBRL - until the BDO-audited, Delaware-domiciled version arrives. Watch August 5: Q2 earnings, guided to roughly $333 million, will be the first quarter fully inside the new tax regime.
The Bottom Line
Curaleaf is the biggest revenue base in US cannabis, the only real international platform, and the most aggressive 280E balance sheet in the sector - a company that has been running its income statement as if rescheduling already happened, and in Q1 started booking the win. If the ALJ recommendation and the DEA Administrator deliver broad Schedule III and the courts leave the partial order standing, Curaleaf's paper profits become real cash economics: roughly $124 million a year of tax burden goes away, owner earnings turn sustainably positive, the uplisting completes, and today's price is defensible. If the courts or the DEA break the other way, the $70 million "profit" was an accounting preview of a movie that never releases - and a $588 million bill comes due against $106 million of cash. The framework to watch, in order: the D.C. Circuit stay ruling, the ALJ's recommended decision and the Administrator's final rule, the August 5 Q2 print, and any uplisting or deconsolidation announcement. The market has already voted for the happy ending at 12-13 times EBITDA. The filing says the jury is still out.
Every figure above is drawn from Curaleaf's SEC filings via the RoboSystems SEC graph (CIK 0001756770, FY2025 40-F filed February 27, 2026), the company's Q1 2026 earnings release and call (May 5, 2026), or attributed news sources, priced as of July 15, 2026. This is not investment advice; no price targets are offered.
This analysis was built with RoboSystems - open-source, queryable SEC filing data for every public company. Get started at robosystems.ai. New customers get 50% off your first month with code CANNABIS50.